Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer
(MedPage Today) -- Adding docetaxel to radiation therapy (RT) improved survival outcomes in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase III randomized trial showed.
At a median follow-up of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 4, 2023 Category: Hematology Source Type: news
Shedding light on the genetic causes of lung cancer
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2019/6/papers/lung-cancer/thumb870603.jpg?itok=qfqhutj5" /><br /><p>When an NIEHS-led team disrupted a stress response pathway in mice, lung squamous cell carcinoma developed, suggesting a treatment target.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
New Imaging Score May Predict Chemo Benefit in Early OPSCC New Imaging Score May Predict Chemo Benefit in Early OPSCC
If validated, this scoring system could help identify patients with oropharyngeal squamous cell carcinoma who can skip chemo. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the submission of a Biologics License... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 4, 2023 Category: Drugs & Pharmacology Source Type: news
Neoadjuvant Immunochemotherapy Promising in Oral SCC Neoadjuvant Immunochemotherapy Promising in Oral SCC
A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Post-op Chemo Has Limited Benefit in Some Esophageal Cancers Post-op Chemo Has Limited Benefit in Some Esophageal Cancers
Patients with stage IIA and IIB esophageal squamous cell carcinoma with lymphovascular invasion but negative lymph nodes do not benefit. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Solid organ transplant patients are at higher risk of skin cancer and require coordinated care, Mayo Clinic researchers find
More than half of all patients who receive solid organ transplants will have an incidence of skin cancer at some point — most often a nonmelanoma cancer, such as basal cell carcinoma or squamous cell carcinoma. This increased risk can be several hundred times higher than in the general population. The increased risk is related to long-term immunosuppressive therapy required for transplanted organ survival, which a ffects the immune system's ability to monitor cells for abnormalities.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 5, 2022 Category: Databases & Libraries Source Type: news
Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first - line treatment of advanced cutaneous squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 24, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news
Nivolumab Promising for Treatment of Advanced Cutaneous SCC
MONDAY, Oct. 24, 2022 -- For advanced cutaneous squamous cell carcinoma (aCSCC), first-line treatment with nivolumab shows robust antitumor activity and good tolerability, according to a study published online Oct. 24 in Cancer.
Rodrigo R. Munhoz,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 24, 2022 Category: Pharmaceuticals Source Type: news
Rare Mesothelioma Cancer Discovered in Quarter Horse
No one is immune to the effects of toxic asbestos fibers, the primary cause of mesothelioma cancer. Not even horses.
Although mesothelioma is a rare cancer in humans, it is even more rare in animals, particularly horses that spend most of their time grazing outdoors. But it still happens.
Both pleural mesothelioma and peritoneal mesothelioma cancer were identified during the autopsy of a 22-year-old gelding quarter horse that had spent much of its working life in equestrian tourism activities.
Animals, an international peer-reviewed journal devoted to veterinary sciences, detailed the rare mesothelioma case report...
Source: Asbestos and Mesothelioma News - October 4, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
No increased perioperative morbidity seen among patients with local regionally advanced oral cavity squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Surgery, Journal, Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
THURSDAY, Sept. 15, 2022 -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma
(MedPage Today) -- PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous squamous cell carcinoma (cSCC), according to research presented here.
Among 79 patients treated... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 13, 2022 Category: Dermatology Source Type: news
Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
MONDAY, Sept. 12, 2022 -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for resectable stage II, III, or IV (M0) cutaneous squamous cell carcinoma had a pathological complete response, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2022 Category: Pharmaceuticals Source Type: news
